CARDIFF, Wales & TOKYO--(BUSINESS WIRE)--Abcellute Ltd (Abcellute) and GeneFrontier Corporation (GeneFrontier) announced today that they have signed an Exclusive Agreement for the manufacture, marketing and distribution of Abcellute’s preserved hepatocyte products into Japan. Under the terms of the agreement, GeneFrontier are also permitted to establish sub-licences with Pharmaceutical and similar companies actively involved in the pre-clinical evaluation of new candidate drugs, for their internal use of the Abcellute cell preservation technology. Detailed financials are not disclosed.
